

Information about Scandion Oncology A/S and the Exercise of Warrants of Series TO 2

Exercise period 4 November 2024 – 18 November 2024



This information brochure should be considered marketing material and does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Scandion Oncology A/S ("Scandion Oncology" or "the Company"). The information brochure is not and should not be regarded as a prospectus under applicable laws and regulations. The invitation to relevant parties to subscribe for units in Scandion Oncology has only been made through the prospectus published by Scandion Oncology on May 31, 2024, which is available on the Company's website, www.scandiononcology.com. Readers are advised to read the prospectus for a description of the risks associated with an investment in the Company. This information brochure may not be published, released, or distributed, directly or indirectly, in or into the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such action would be illegal or subject to legal restrictions.

About Scandion Oncology

Scandion Oncology A/S, is a Danish public limited liability company organized under the laws of Denmark. The Company's shares are listed on Nasdaq First North Growth Market Sweden. Scandion Oncology discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. The Company is at the forefront of this field, developing novel medicines that address cancer's resistance against treatment. The aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer. As a biotech company, Scandion Oncology focuses on clinical development of its most promising compound to achieve proof-of-concept and confirmation hereof in pivotal trials, both independently and in partnerships. Scandion Oncology is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials.

Scandion's Progress with SCO-101 and Strategic Focus on Business Development

Scandion has made significant progress with its lead compound SCO-101 in combination with FOLFIRI chemotherapy for treating metastatic colorectal cancer (mCRC). The CORIST Phase IIa Part 3 trial successfully

established the maximum tolerated dose (MTD) ahead of schedule, confirming the safety of SCO-101. Additionally, the PANTAX Phase Ib trial for advanced pancreatic cancer reaffirmed SCO-101's strong safety profile. With positive results, Scandion is now prioritizing business development and strategic partnerships, collaborating with Back Bay Life Science Advisors to explore growth opportunities. SCO-101's unique mechanism of action and continued progress highlight its potential for future success.

Use of Proceeds TO 2

The proceeds from the exercise of warrants of series TO 2 will be used to progress the CORIST study and further strengthen business development activities, depending on the level of the net proceeds.

Comment from CEO

"Data from the CORIST part 3 continuation trial showed that the endpoint of establishing a maximum tolerated dose (MTD) was established ahead of schedule. Setting the MTD was a final, important achievement, giving us the best dose to use in SCO-101's next development steps, and in our ongoing partnering discussions"
Francois R. Martelet, CEO

Scandion Oncology A/S in brief

OUR MISSION

To bring new medicines to patients in order to overcome cancer drug resistance and improve lives for cancer patients and their families

7,260
SHAREHOLDERS
SEPTEMBER 30, 2024

35 MSEK
MARKET CAP
SEPTEMBER 30, 2024

23 MSEK
CASH POSITION
SEPTEMBER 30, 2024



2 CLINICAL PROGRAMS

CORIST currently in Phase IIa, (~100 subjects dosed),
PANTAX currently in Phase Ib



LISTED STOCK EXCHANGE

Nasdaq First North Stockholm
Ticker: SCOLST



PIPELINE

SCO-101, SCO-201, 800 analogues



PEOPLE

Current staff of 4 employees
as of September 30, 2024
Office in Copenhagen, Denmark



CANCER INDICATIONS

Colorectal, Pancreatic, Gastric and others



TERMS AND CONDITIONS

Terms and Conditions for Warrant Series TO 2

One (1) warrant series TO 2 entitles the holder to subscribe for one (1) new share in the Company to a subscription price corresponding to seventy (70) per cent of the volume weighted average price of the Company's share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the shares' nominal value and not higher than 125 per cent of the subscription price in the rights issue carried out by the Company during the second quarter of 2024. The volume-weighted average price of the Company's shares during the pricing period amounted to approximately 0.12 SEK, resulting in the subscription price being set at 0.12 SEK per share. If all warrants of series TO 2 are exercised, the Company will receive net proceeds of approximately 17.2 MSEK before deduction of issuance costs.

Exercise Period

Subscription of shares through the exercise of warrants of series TO 2 shall take place during the period from 4 November 2024, to 18 November 2024. Please note that warrants of series TO 2 that are not sold by 14 November 2024, or exercised by 18 November 2024, will expire without value. Please note that certain nominees might close their subscription earlier than on 18 November 2024.

Shares, Share Capital, and Dilution Effect

In the event all warrants of series TO 2 are exercised, the number of shares in the Company will increase by 143,416,179 shares, from 231,928,544 to 375,344,723 shares, and the share capital will increase by 10,541,089.15650 DKK, from 17,046,747.9840 DKK to 27,587,837.1405 DKK. This corresponds to a maximum dilution effect from the warrants of approximately 38.2 per cent.

Announcement of Outcome

The outcome of the exercise of the warrants of series TO 2 will be announced through a press release, expected around 20 November 2024.

Exercise of Warrants

Subscription Notification - Directly Registered Warrant Holders

Notification for subscription is made via a subscription form available on the websites of Vator Securities and Scandion Oncology. Payment will be made according to the instructions on the subscription form. Both the subscription form and payment must be received by Vator Securities no later than 15:00 on 18 November 2024.

Subscription Notification - Custodial Registered Warrant Holders

If the warrant holder has their warrants in a custody account, investment savings account (Swe. *Investeringssparkonto*), or endowment insurance (custodial registered ownership – Swe. *kapitalförsäkring*), the subscription and payment will be processed through the custodian, who will provide further instructions on how to exercise the warrants. The warrant holder should contact their custodian well in advance for additional instructions regarding the exercise of the warrants.

Complete Terms and Information

Scandion Oncology's prospectus and terms for the warrants of series TO 2 are available for download at www.scandiononcology.com.

Important Dates

Exercise period begins:	4 November 2024
Last day for trading warrants (TO 2):	14 November 2024
Exercise period ends:	18 November 2024
Planned date for announcement of outcome:	20 November 2024
Planned date for conversion to shares:	6 December 2024